Company Profile
Inventiva Stock Price, News & Analysis
- Ticker:
- IVA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- France and listed in the U
Stock performance
4.66 USD (-1.27%)
Close
Last updated: August 6, 2026
855M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, IVA closed down 1.27% at $4.66. No new same-company headline was identified in the current news window.
Company overview
Business overview
Inventiva is a biotechnology company focused on liver disease and fibrotic conditions, especially metabolic and inflammatory pathways. Its story is centered on MASH and related liver biology.
Geographic Base and Sector Classification
Headquartered in France and listed in the U.S. as an ADR, Inventiva has a global specialty-biopharma profile.
Business Model Characteristics
The company depends on clinical data, dose selection, and the possibility of building a durable liver-disease franchise.
Position Within the Biotechnology Landscape
Inventiva is a catalyst-sensitive liver-disease name whose stock reacts strongly to clinical progress.
Future catalysts
Inventiva’s catalyst is lanifibranor, especially the MASH / liver-disease development path and any follow-up that keeps the program on track. The market will watch whether the asset can continue to support a credible metabolic-liver story.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Inventiva (IVA)?
Inventiva (IVA) most recently closed at 4.66 USD, a -1.27% move versus the previous session.
What is the market cap of Inventiva (IVA)?
Inventiva currently has a market capitalization of 855M USD on BioPharmSignal.
What does Inventiva do?
Inventiva is a biotechnology company focused on liver disease and fibrotic conditions, especially metabolic and inflammatory pathways. Its story is centered on MASH and related liver biology.
On which exchange is IVA stock listed?
Inventiva (IVA) is associated with NASDAQ, France and listed in the U, Biopharma.
What is Inventiva?
Inventiva’s catalyst is lanifibranor, especially the MASH / liver-disease development path and any follow-up that keeps the program on track.
Which conditions is Inventiva targeting with Inventiva?
Inventiva is associated with metabolic disease based on its company overview and current catalyst commentary.
How does Inventiva describe recent progress with Inventiva?
Inventiva’s catalyst is lanifibranor, especially the MASH / liver-disease development path and any follow-up that keeps the program on track.
What future catalysts are investors watching for Inventiva?
Inventiva’s catalyst is lanifibranor, especially the MASH / liver-disease development path and any follow-up that keeps the program on track. The market will watch whether the asset can continue to support a credible metabolic-liver story.